Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson’s disease patients treated with levodopa/carbidopa

Hansen, Ryan N.; Suh, Kangho; Serbin, Michael; Sullivan, Sean D.

doi:10.1080/13696998.2021.1916750

Cited by 7 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, since only one head-to-head comparison study of opicapone and entacapone (BIPARK-1) has been conducted [ 8 ], further studies on the efficacy and safety of several COMT inhibitors are required. According to a cost-effectiveness simulation study comparing opicapone with entacapone, opicapone was more effective in reducing off-time than entacapone and had a 60–65% probability of being cost-effective [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis

Kwak

Park

Kang

et al. 2022

JPD

View full text Add to dashboard Cite

Background: Long-term levodopa administration for treating Parkinson’s disease (PD) may shorten the duration of effect and cause dyskinesias, inducing the need for catechol-O-methyltransferase (COMT) inhibitors as adjuvant therapy. Objective: We provide pooled scientific evidence highlighting the efficacy and safety of opicapone, a newly approved COMT inhibitor, as an adjuvant to levodopa. Methods: We searched Ovid Medline, Embase, and Cochrane databases for relevant reports. Efficacy and safety were evaluated as off-time reduction and risk ratio (RR) of dyskinesia, respectively. Data were independently extracted using predefined criteria. Selected placebo-controlled trials were divided into double-blind and open-label periods. Using a random-effects model, the mean difference (MD) of the off-time reduction (efficacy), RR for the occurrence of dyskinesia, and on-time without/with troublesome dyskinesia (TD; safety assessment) were compared between opicapone and placebo groups. Results: Five studies from three randomized controlled trials were included, and a meta-analysis was performed with 407 patients receiving opicapone 50 mg and 402 patients receiving placebo. Compared with the placebo, opicapone (50 mg) reduced off-time by 49.91 min during the double-blind period (95% confidence intervals [CIs] = –71.39, –28.43; I2 = 0%). The RR of dyskinesia was 3.43 times greater in the opicapone 50 mg group than in the placebo group (95% CI = 2.14, 5.51; I = 0%). Compared with the placebo, opicapone increased the on-time without TD by 44.62 min (95% CI = 22.60, 66.64; I2 = 0%); the on-time increase with TD did not differ between treatments. Conclusion: Opicapone can play a positive role as an adjuvant to levodopa in patients with PD by reducing off-time and prolonging on-time without PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis

Kwak

Park

Kang

et al. 2022

JPD

View full text Add to dashboard Cite

show abstract

“…To evaluate the affinity of the compounds under study with each of the chosen targets, a comparison was made with the PDB ligand and positive control (a drug already used with activity at the targets reported in the literature). The positive controls used were respectively: L-DOPA (α-synuclein) [ 154 ], Pramipexole (D2 Dopamine Receptor) [ 155 ], Bromocriptine (D1 Dopamine Receptor) [ 156 ], Istradefylline (Adenosine A2A Receptor) [ 157 ], Entacapone (COMT Catechol O-methyltransferase) [ 158 ], and Rasagiline (Monoamine Oxidase MAO) [ 95 ].…”

Section: Methodsmentioning

confidence: 99%

Computational Studies Applied to Linalool and Citronellal Derivatives Against Alzheimer's and Parkinson's Disorders: A Review with Experimental Approach

Silva

Andrade

Sousa

et al. 2023

View full text Add to dashboard Cite

Introduction: Alzheimer's and Parkinson's are neurodegenerative disorders that affect a great number of people around the world, seriously compromising the quality of life of individuals, due to motor and cognitive damage. In these diseases, pharmacological treatment is used only to alleviate symptoms. This emphasizes the need to discover alternative molecules for use in prevention. Objective: Using Molecular Docking, this review aimed to evaluate the anti-Alzheimer’s and anti- Parkinson’s activity of linalool and citronellal, as well as their derivatives. Methodology: Before performing Molecular Docking simulations, the compounds’ pharmacokinetic characteristics were evaluated. For Molecular Docking, 7 chemical compounds derived from citron- ellal, and 10 compounds derived from linalool, and molecular targets involved in Alzheimer's and Parkinson's pathophysiology were selected. Results: According to the Lipinski rules, the compounds under study presented good oral absorption and bioavailability. For toxicity, some tissue irritability was observed. For Parkinson-related targets, the citronellal and linalool derived compounds revealed excellent energetic affinity for α-Synuclein, Adenosine Receptors, Monoamine Oxidase (MAO), and Dopamine D1 receptor proteins. For Alzheimer disease targets, only linalool and its derivatives presented promise against BACE enzyme activity. Conclusion: The compounds studied presented high probability of modulatory activity against the dis- ease targets under study, and are potential candidates for future drugs.

show abstract

COMT Inhibitors in the Management of Parkinson’s Disease

2022

View full text Add to dashboard Cite

Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson’s disease patients treated with levodopa/carbidopa

Abstract: Cost-effectiveness outcomes included incremental cost per OFF-time hours avoided, cost per life year gained, and cost per quality-adjusted life year (QALY) gained. Outcomes were projected over a 25-year lifetime horizon and discounted at 3% annually.

Cited by 7 publications

References 21 publications

Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis

Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis

Computational Studies Applied to Linalool and Citronellal Derivatives Against Alzheimer's and Parkinson's Disorders: A Review with Experimental Approach

COMT Inhibitors in the Management of Parkinson’s Disease

Contact Info

Product

Resources

About